Dusigitumab
Based on 1 Customer Validation
Dusigitumab is a fully human IgG2λ monoclonal antibody that targets IGF-1 and IGF-2 with picomolar binding affinity. Dusigitumab blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R as well as activation of IR-A, thereby inhibiting the activation of downstream signaling pathways. Dusigitumab is applicable to research related to advanced solid tumors and hormone receptor-positive metastatic breast cancer.
For research use only. We do not sell to patients.
- Purity : 96.37%
- CAS No.: 1204390-13-5
- Molecular Weight:144.24 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG2 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IGF-1&IGF-2
In Vitro
Gene ID
Accession
P01344-1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG2 lambda
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IGF-I/IGF-1 Protein, Human can bind Dusigitumab. The EC50 for this effect is 145.7 ng/mL. -
Flow cytometric analysis of 1X106 HepG2 cells with Dusigitumab (HY-P99867, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 lambda (HY-P991206, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1204390-13-5
-
Appearance Liquid
-
Molecular Weight 144.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Dusigitumab]
-
Synonyms
MEDI-573
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. de Bono J, et al. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer. 2020;122(9):1324-1332. [Content Brief]
[2]. Osher E, et al. Therapeutic Targeting of the IGF Axis. Cells. 2019;8(8):895. Published 2019 Aug 14. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)